UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
November 17, 2026
Commission File Number: 000-17444
Akzo Nobel N.V.
Christian Neefestraat 2
1077 WW Amsterdam
The Netherlands
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
EXPLANATORY NOTE
As previously disclosed, on November 18, 2025, Akzo
Nobel N.V. (“AkzoNobel”) entered into a Merger Agreement (as amended by Amendment No. 1 to Merger Agreement, dated May 27,
2026, and Amendment No. 2 to Merger Agreement, dated July 23, 2026) with Axalta Coating Systems Ltd. (“Axalta”), pursuant
to which, on the terms and subject to the conditions set forth therein, AkzoNobel and Axalta have agreed to combine their respective businesses
in a merger of equals (the “Merger”), with AkzoNobel (upon completion of the Merger, “MergeCo”) serving as the
combined company’s listed parent.
AkzoNobel today commenced a private offering of notes
(the “Notes Offering”) by Akzo Nobel, Inc., a subsidiary of AkzoNobel (the “Notes Issuer”), the net proceeds of
the Notes Offering are intended to be used for general corporate purposes and may also be used to refinance, from time to time, in whole
or in part, (i) the term loans due December 20, 2029 issued and outstanding pursuant to the credit agreement, dated February 1, 2013,
by and among Axalta Coating Systems Dutch Holding B.V., Axalta Coating Systems U.S. Holdings, Inc., Axalta Coating Systems U.S., Inc.,
Axalta, as borrowers, the lenders from time to time party thereto and Barclays Bank PLC, as administrative agent and collateral agent,
as amended from time to time, and (ii) Axalta’s outstanding $500 million senior notes due 2027, (iii) Axalta’s outstanding
$700 million senior notes due 2029 and/or (iv) Axalta’s outstanding $500 million senior notes due 2031, in each case following the
completion of the Merger.
AkzoNobel’s offering memorandum for the Notes
Offering incorporates by reference unaudited pro forma condensed combined financial information giving effect to the Merger and the related
transactions, consisting of (i) the unaudited pro forma condensed combined balance sheet of MergeCo as of September 30, 2026, giving effect to the Merger and the
related transactions as if they had been consummated on September 30, 2026, and the unaudited pro forma condensed combined statement of
income of MergeCo for the nine months ended September 30, 2026, giving effect to the Merger and the related transactions as if they had
been consummated on January 1 2025, in each case together with the notes thereto, and (ii) the unaudited pro forma condensed combined
statement of income of MergeCo for the year ended December 31, 2025, giving effect to the Merger and the related transactions as if they had been consummated on January 1, 2025.
The notes and the guarantee in the Notes Offering
have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or any state securities
laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation
S under the Securities Act) except in transactions exempt from, or not subject to, the registration requirements of the Securities Act.
Accordingly, the notes and the guarantee are being offered and sold only to persons reasonably believed to be qualified institutional
buyers in accordance with Rule 144A under the Securities Act and outside the United States to non-U.S. persons in reliance on Regulation
S under the Securities Act. Pursuant to a registration rights agreement expected to be entered into in connection with the issuance of
the notes, the Notes Issuer and AkzoNobel will be required to use commercially reasonable efforts to file with the U.S. Securities and
Exchange Commission and cause to become effective a registration statement relating to an offer to exchange the notes for new notes having
terms substantially identical to the notes registered under the Securities Act, or, in certain circumstances, to register the resale of
the notes.
This announcement does not constitute an offer to
sell or the solicitation of an offer to buy the notes or any other security, nor shall it constitute an offer, solicitation or sale in
any jurisdiction in which such offer, solicitation or sale is unlawful. Any offers of the notes or the guarantee will be made only by
means of a private offering memorandum.
This announcement is directed only at persons who
(i) are outside the United Kingdom, (ii) have professional experience in matters relating to investments falling within Article 19(5)
of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Financial Promotion Order”),
(iii) fall within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Financial
Promotion Order or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section
21 of the Financial Services and Markets Act 2000 (“FSMA”)) in connection with the issue or sale of any notes may otherwise
lawfully be communicated or caused to be communicated (all such persons together being referred to as “relevant persons”).
This announcement must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to
which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.
In any member state of the European Economic Area
(the “EEA”), this announcement is only addressed to and directed at persons who are “qualified investors” within
the meaning of Regulation (EU) 2017/1129 (the “Prospectus Regulation”). In the United Kingdom, any offer of the notes will
be made pursuant to an exemption under the Public Offers and Admissions to Trading Regulations 2024 (the “POATRs”) from the
prohibition on offers of securities to the public. This announcement does not constitute an advertisement for the purposes of the Prospectus
Regulation or a prospectus for the purposes of the POATRs.
The notes are not intended to be offered, sold, distributed
or otherwise made available to, and should not be offered, sold, distributed or otherwise made available to, any retail investor in the
EEA or the United Kingdom. No key information document required by Regulation (EU) No 1286/2014 (as amended) has been prepared, and no
disclosure document required by the FCA Product Disclosure Sourcebook (“DISC”) has been or will be prepared, for offering,
selling or distributing the notes or otherwise making them available to retail investors in the EEA or the United Kingdom, respectively.
Forward-Looking Statements
This announcement contains forward-looking statements,
including statements regarding the proposed offering, the intended use of proceeds and the expected timing and completion of the Merger.
These statements are based on current plans, estimates and expectations and are subject to risks, uncertainties and assumptions, many
of which are outside the control of AkzoNobel, and actual results may differ materially from those expressed or implied. Undue reliance
should not be placed on these statements, which speak only as of the date of this announcement, and AkzoNobel undertakes no obligation
to update them, except as required by applicable law. Neither the content of AkzoNobel’s website nor any website accessible by hyperlinks
on AkzoNobel’s website is incorporated in, or forms part of, this announcement.
The following exhibit is furnished
herewith:
Exhibit
Index
| Exhibit Number |
Description of Exhibit |
| 99.1 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF AKZO NOBEL N.V. RELATING TO AKZO NOBEL N.V. AND AXALTA COATING SYSTEMS LTD. MERGER OF EQUALS |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| |
|
|
|
|
| Date: November 17, 2026 |
|
|
By: |
/s/ Grégoire Poux-Guillaume |
| |
|
|
|
Name: |
Grégoire Poux-Guillaume |
| |
|
|
|
Title: |
Chief Executive Officer |
| Date: November 17, 2026 |
|
|
By: |
/s/ Maarten de Vries |
| |
|
|
|
Name: |
Maarten de Vries |
| |
|
|
|
Title: |
Chief Financial Officer |
Exhibit 99.1
UNAUDITED
PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF AKZO NOBEL N.V. RELATING TO AKZO NOBEL N.V. AND AXALTA COATING SYSTEMS LTD. MERGER
OF EQUALS
The following unaudited pro forma condensed combined
financial information of Akzo Nobel N.V. (the “Pro Forma Financial Information”), including the unaudited pro forma condensed
combined balance sheet as of September 30, 2026 and the unaudited pro forma condensed combined statement of income for the nine months
ended September 30, 2026 of Akzo Nobel N.V. (“AkzoNobel” and, together with its subsidiaries, “AkzoNobel Group”),
has been prepared to illustrate the effect of the proposed all-stock merger of equals (the “transaction”) between AkzoNobel
and Axalta Coating Systems Ltd. (“Axalta” and, together with its subsidiaries, “Axalta Group”) pursuant to the
merger agreement, originally dated as of November 18, 2025 and as amended on May 27, 2026 and July 23, 2026, by and between AkzoNobel
and Axalta (the “Merger Agreement”), which was approved by shareholders of AkzoNobel and Axalta at their extraordinary general
meeting and special general meeting, respectively, each held on August 5, 2026, and the completion of which remains subject to the receipt
of the required regulatory approvals and satisfaction of other customary closing conditions. As part of obtaining the required regulatory
clearances for the transaction, AkzoNobel has announced that it is planning to divest its European vehicle refinishing business, and Axalta
has announced that it is planning to divest its North American building products business. These divestitures have not been reflected
for purposes of the Pro Forma Financial Information. For more information about the transaction, see the section entitled “The Merger
Agreement—Conditions to the Merger” in AkzoNobel’s registration statement on Form F-4 filed with the U.S. Securities
and Exchange Commission (the “SEC”) on May 27, 2026 (File No. 333-296290), as amended on June 18, 2026, and declared effective
by the SEC on June 23, 2026, in connection with the transaction, including the proxy statement/prospectus filed with the SEC on June 24,
2026, and as supplemented from time to time (the “Form F-4”).
The Pro Forma Financial Information
was derived from and should be read in conjunction with:
| · | the AkzoNobel Group unaudited condensed consolidated financial statements as of September 30, 2026 and
for the nine months ended September 30, 2026, and the sections entitled “Financial Highlights,” “Performance Coatings,”
“Decorative Paints” and “Alternative Performance Measures,” contained in AkzoNobel’s interim report for
the nine months ended September 30, 2026, furnished with the SEC on Form 6-K on October 21, 2026 (File No. 000-17444); and |
| · | the Axalta Group unaudited condensed consolidated financial statements as of September 30, 2026 and for
the nine months ended September 30, 2026, and the section entitled “Management’s Discussion and Analysis of Financial Condition
and Results of Operations,” contained in Axalta’s Quarterly Report on Form 10-Q for the nine months ended September 30, 2026,
filed with the SEC on October 29, 2026 (File No. 001-36733). |
The unaudited pro forma condensed
combined balance sheet as of September 30, 2026 gives effect to the transaction as if it had occurred on September 30, 2026. The unaudited
pro forma condensed combined statement of income for the nine months ended September 30, 2026 gives effect to the transaction as if it
had occurred on January 1, 2025.
The Pro Forma Financial
Information has been prepared in accordance with Article 11 of Regulation S-X, except for the 2025 annual period. The Pro Forma
Financial Information should be read together with the accompanying notes. Such notes describe, amongst others, the basis, assumptions
and estimates related to the adjustments to the Pro Forma Financial Information.
The Pro Forma Financial Information
is not necessarily indicative of what the financial position or results of operations of AkzoNobel Group after giving effect to the transaction
actually would have been had the transaction been completed as of the dates indicated. In addition, the Pro Forma Financial Information
does not purport to project the future financial position or operating results of AkzoNobel and its subsidiaries, including Axalta and
its subsidiaries, following completion of the transaction (“MergeCo Group”). The pro forma adjustments are based on the best
information available at the time of the preparation of the relevant Pro Forma Financial Information and certain assumptions that AkzoNobel
Group believes to be reasonable.
The Financing
Transactions
As part of the Merger Agreement, it was agreed
that AkzoNobel will declare and pay the pre-completion distribution (as defined below) to AkzoNobel’s shareholders prior to completion.
Furthermore, the consummation of the transaction
will constitute a “Change of Control” under the Axalta credit agreement. Pursuant to the Merger Agreement, AkzoNobel agreed
to, in consultation with Axalta, use reasonable best efforts to obtain funds to, among other things, refinance the Axalta 2029 dollar
term loans due December 20, 2029 issued pursuant to the Axalta credit agreement (as defined below) (the “Axalta 2029 Dollar Term
Loans”) prior to, or substantially concurrently with, consummation of the transaction (“completion”).
On March 25, 2026, AkzoNobel issued 4.000% fixed
rate senior unsecured notes due March 25, 2031 in an aggregate principal amount of €600 million (the “New 2031 Senior Notes”),
and on June 16, 2026, AkzoNobel issued 3.625% fixed rate senior unsecured notes due June 16, 2029 in an aggregate principal amount of
€750 million (the “New 2029 Senior Notes” and, together with the New 2031 Senior Notes, the “New Senior Notes”)
pursuant to AkzoNobel’s Euro Medium Term Note Programme.
AkzoNobel intends to finance the pre-completion
distribution, as well as the required refinancing of the Axalta 2029 Dollar Term Loans through a combination of cash generated from operations,
cash on hand and the placement of bonds and commercial paper (including the New Senior Notes). Should such placements not yet be completed
prior to completion, or be in amounts insufficient to fund such items, a bridge financing facility may be put in place. As such and based
on information known at the time of this report, AkzoNobel is reflecting the source of this funding as coming from cash on hand in the
amount of €900 million, the New 2031 Senior Notes of €600 million, the New 2029 Senior Notes in the amount of €750 million
with the remaining funds coming from the issuance of additional debt to fund the transaction financing prior to completion and for purposes
of this report.
Accounting for
the Transaction
The transaction will be accounted
for as a business combination using the acquisition method of accounting in accordance with IFRS 3, Business Combinations (“IFRS
3”). IFRS 3 requires that one of the two companies in a transaction be designated as the acquirer for accounting purposes based
on the evidence available. AkzoNobel will be treated as the acquiring entity for accounting purposes. In identifying AkzoNobel as the
acquiring entity for accounting purposes, AkzoNobel and Axalta took into account the anticipated relative voting rights of all equity
instruments of MergeCo (as defined below), the intended composition of the governing body and senior management of MergeCo and the relative
size of the companies. In assessing the size of each of the companies, AkzoNobel’s and Axalta’s management evaluated various
metrics, including, but not limited to, revenue, profit before taxation, total assets and market capitalization. Accordingly, AkzoNobel
will record assets acquired, including identifiable intangible assets, and liabilities assumed from Axalta at their respective fair values
at the completion date (as defined below). Any excess of the purchase price over the net fair value of such assets and liabilities will
be recorded as goodwill.
The financial condition and
results of operations of AkzoNobel Group after completion will reflect Axalta Group after completion, but will not be restated retroactively
to reflect the historical financial condition or results of operations of Axalta Group. The earnings of AkzoNobel Group following completion
will reflect acquisition accounting adjustments, including the effect of changes in the carrying value for assets and liabilities on depreciation
expense, amortization expense and interest expense. Goodwill will not be amortized but will be tested for impairment at least annually,
and all tangible and intangible assets including goodwill will be tested for impairment when certain indicators are present. If, in the
future, MergeCo determines that tangible or intangible assets (including goodwill) are impaired, MergeCo would record an impairment charge
at that time.
Basis of Pro Forma
Presentation
The Pro Forma Financial Information
appearing below does not consider any potential effects of changes in market conditions on revenues or expense efficiencies, among other
factors. In addition, as explained in more detail in the accompanying notes, the preliminary allocation of the pro forma purchase price
reflected in the Pro Forma Financial Information is subject to adjustment and may vary significantly from the actual purchase price allocation
that will be recorded upon completion.
The Pro Forma Financial Information
has been prepared based on the aforementioned historical consolidated financial statements and the assumptions and adjustments as described
in the notes to the Pro Forma Financial Information. The pro forma adjustments reflect transaction accounting adjustments related to the
transaction and the financing transactions, which are discussed in further detail below. Amounts presented reflect the accounting for
the transaction. These pro forma adjustments are preliminary, subject to further revision as additional information becomes available
and additional analyses are performed and have been made solely for the purpose of providing the Pro Forma Financial Information. Therefore,
the Pro Forma Financial Information is presented for illustrative purposes only and does not purport to represent MergeCo Group’s
consolidated results of operations or consolidated financial position that would actually have occurred had the transaction been consummated
on the dates assumed or to project MergeCo Group’s consolidated results of operations or consolidated financial position for any
future date or period.
In addition, for purposes of the Pro Forma Financial
Information, the applicable historical financial statements of Axalta Group have been reclassified to align to the financial statement
presentation of AkzoNobel Group, and preliminarily adjusted for material accounting policy differences between U.S. generally accepted
accounting principles (“U.S. GAAP”) and IFRS Accounting Standards as issued by the International Accounting Standards Board
(“IFRS”) as applied by AkzoNobel Group identified to date.
The Pro Forma Financial Information
is presented for illustrative purposes only and does not reflect the costs of any management adjustments, including integration activities
or cost savings or synergies that may be achieved because of the transaction.
AkzoNobel Group and Axalta
Group have not had any material relationships prior to the transaction. Accordingly, no pro forma adjustments were required to eliminate
activities between the companies.
UNAUDITED PRO FORMA
CONDENSED COMBINED BALANCE SHEET AS OF SEPTEMBER 30, 2026
|
(€ millions,
unless otherwise stated)
|
AkzoNobel Group
Historical
As Reported (IFRS)
|
Axalta Group
Historical
As Adjusted IFRS)
|
Transaction
Accounting Adjustments
|
|
Transaction
Financing Adjustments
|
|
Pro Forma
Combined
|
Convenience
Translation
|
| |
|
(Note 2) |
|
|
|
|
|
($) |
| Assets |
|
|
|
|
|
|
|
|
| Non-current assets |
|
|
|
|
|
|
|
|
| Intangible assets |
3,544 |
2,604 |
4,144 |
(A) |
|
|
10,292 |
11,685 |
| Property, plant and equipment |
2,043 |
1,017 |
584 |
(A) |
|
|
3,644 |
4,137 |
| Right-of-use assets |
280 |
139 |
|
|
|
|
419 |
476 |
| Other non-current assets |
1,744
|
394
|
|
|
|
|
2,138
|
2,428
|
| Total non-current assets |
7,611
|
4,154
|
4,728
|
|
–
|
|
16,493
|
18,726
|
| Current assets |
|
|
|
|
|
|
|
|
| Inventories |
1,639 |
748 |
162 |
(A) |
|
|
2,549 |
2,894 |
| Trade and other receivables |
2,651 |
1,288 |
|
|
|
|
3,939 |
4,472 |
| Current tax assets |
191 |
45 |
|
|
|
|
236 |
268 |
| Short-term investments |
266 |
– |
|
|
|
|
266 |
302 |
| Cash and cash equivalents |
3,146 |
577 |
(159) |
(B) |
1,102 |
(E) |
1,281 |
1,454 |
| |
|
|
(2,236) |
(C) |
(1,116) |
(F) |
|
|
| |
|
|
(33) |
(D) |
|
|
|
|
| Assets held for sale |
515
|
–
|
|
|
|
|
515
|
585
|
| Total current assets |
8,408
|
2,658
|
(2,266)
|
|
(14)
|
|
8,786
|
9,975
|
| Total assets |
16,019
|
6,812
|
2,462
|
|
(14)
|
|
25,279
|
28,701
|
| Equity and Liabilities |
|
|
|
|
|
|
|
|
| Equity |
|
|
|
|
|
|
|
|
| Shareholders' equity |
4,853 |
2,309 |
(2,309) |
(A) |
|
|
8,856 |
10,054 |
| |
|
|
6,414 |
(A) |
|
|
|
|
| |
|
|
(159) |
(B) |
|
|
|
|
| |
|
|
(2,236) |
(C) |
|
|
|
|
| |
|
|
(16) |
(D) |
|
|
|
|
| Non-controlling interests |
166
|
40
|
(5)
|
(A)
|
|
|
201
|
228
|
| Group equity |
5,019
|
2,349
|
1,689
|
|
–
|
|
9,057
|
10,282
|
| Noncurrent liabilities |
|
|
|
|
|
|
|
|
| Provisions and deferred tax liabilities |
1,133 |
450 |
790 |
(A) |
|
|
2,373 |
2,694 |
| Long-term borrowings |
5,501
|
2,251
|
|
|
(1,099)
|
(F) |
6,653
|
7,553
|
| Total non-current liabilities |
6,634
|
2,701
|
790
|
|
(1,099)
|
|
9,026
|
10,247
|
| Current liabilities |
|
|
|
|
|
|
|
|
| Short-term borrowings |
1,001 |
483 |
|
|
1,102 |
(E) |
2,569 |
2,917 |
| |
|
|
|
|
(17) |
(F) |
|
|
| Trade and other payables |
2,941 |
1,197 |
|
|
|
|
4,138 |
4,698 |
| Current tax liabilities |
139 |
53 |
|
|
|
|
192 |
219 |
| Current portion of provisions |
149 |
29 |
(17) |
(D) |
|
|
161 |
184 |
| |
|
|
|
|
|
|
|
|
| Liabilities held for sale |
136
|
–
|
|
|
|
|
136
|
154
|
| Total current liabilities |
4,366
|
1,762
|
(17)
|
|
1,085
|
|
7,196
|
8,172
|
| Total equity and liabilities |
16,019
|
6,812
|
2,462
|
|
(14)
|
|
25,279
|
28,701
|
The accompanying notes are an
integral part of this Pro Forma Financial Information.
UNAUDITED PRO FORMA
CONDENSED COMBINED STATEMENT OF INCOME FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026
|
(€ millions,
unless otherwise stated)
|
AkzoNobel Group
Historical
As Reported
(IFRS)
|
Axalta Group
Historical
As Adjusted (IFRS)
|
Transaction
Accounting Adjustments
|
|
Transaction
Financing Adjustments
|
|
Pro Forma
Combined
|
Convenience
Translation
|
| |
|
(Note 2) |
|
|
|
|
|
($) |
| Continuing operations |
|
|
|
|
|
|
|
|
| Revenue |
7,513 |
3,369 |
|
|
|
|
10,882 |
12,355 |
| Cost of sales |
(4,433)
|
(1,798)
|
(43)
|
(AA) |
|
|
(6,274)
|
(7,123)
|
| Gross profit |
3,080
|
1,571
|
(43)
|
|
–
|
|
4,608
|
5,232
|
| Selling, general and administrative (SG&A) costs |
(2,453) |
(1,076) |
(92) |
AA) |
|
|
(3,621) |
(4,111) |
| Others results |
(272)
|
(79)
|
|
|
|
|
(351)
|
(399)
|
| Operating income |
355
|
416
|
(135)
|
|
–
|
|
636
|
722
|
| Finance income and expenses |
(114) |
(101) |
|
|
(69) |
(CC) |
(231) |
(262) |
| |
|
|
|
|
53 |
(DD) |
|
|
| Results from associates |
26
|
1
|
|
|
|
|
27
|
31
|
| Profit before tax |
267
|
316
|
(135)
|
|
(16)
|
|
432
|
491
|
| Income tax |
(192)
|
(79)
|
34
|
(BB) |
4
|
(BB) |
(233)
|
(265)
|
| Profit for the period |
75
|
237
|
(101)
|
|
(12)
|
|
199
|
226
|
| Attributable to |
|
|
|
|
|
|
|
|
| Shareholders of the company |
56 |
236 |
(101) |
|
(12) |
|
179 |
203 |
| Non–controlling interests |
19
|
1
|
|
|
|
|
20
|
23
|
| Profit for the period |
75
|
237
|
(101)
|
|
(12)
|
|
199
|
226
|
| Weighted average number of common shares |
|
|
|
|
|
|
|
|
| Basic |
171.3 |
213.9 |
|
|
|
|
311.2 |
311.2 |
| Diluted |
171.3 |
214.8 |
|
|
|
|
311.8 |
311.8 |
| Earnings per share |
|
|
|
|
|
|
|
|
| Basic |
0.32 |
1.10 |
|
|
|
|
0.58 |
0.65 |
| Diluted |
0.31 |
1.10 |
|
|
|
|
0.57 |
0.65 |
The accompanying notes are an
integral part of this Pro Forma Financial Information.
NOTES
TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
1. Basis of Presentation
The pro forma adjustments have been prepared as
if completion had occurred on September 30, 2026 in the case of the unaudited pro forma condensed combined balance sheet, and, in the
case of the unaudited pro forma condensed combined statement of income, as if the transaction had been consummated on January 1, 2025.
The Pro Forma Financial Information
has been prepared assuming the acquisition method of accounting in accordance with IFRS 3. Under this method, Axalta Group’s assets
and liabilities will be recorded at their respective fair values. The pro forma adjustments are preliminary, subject to further revision
as additional information becomes available and additional analyses are performed and have been made solely for the purpose of providing
the Pro Forma Financial Information. Therefore, the Pro Forma Financial Information is presented for illustrative purposes only and does
not purport to represent MergeCo Group’s consolidated results of operations or consolidated financial position that would actually
have occurred had the transaction been consummated on the dates assumed or to project MergeCo Group’s consolidated results of operations
or consolidated financial position for any future date or period.
2. Presentation Adjustments to Axalta Group’s
Historical As Reported Financial Statements
Axalta Group’s historical
balances were derived from their historical financial statements described above and are presented in accordance with U.S. GAAP and in
the reporting currency of USD. The table below presents adjustments to align Axalta Group’s historical financial statements with
AkzoNobel Group’s, which are presented in accordance with IFRS and in the reporting currency of EUR.
During the preparation of
the Pro Forma Financial Information, AkzoNobel Group performed a preliminary review of Axalta Group’s financial information to identify
differences in financial statement presentation and accounting policy differences as compared to the presentation of AkzoNobel Group.
Based on the information currently available, certain adjustments have been made to Axalta Group’s historical financial statements
to conform to AkzoNobel Group’s presentation. Upon consummation of the transaction, further review of Axalta Group’s financial
statements may result in additional adjustments, which could be materially different from the amounts set forth in the Pro Forma Financial
Information presented herein.
Refer to the table below
for preliminary reconciliation of the historical financial information of Axalta Group to AkzoNobel Group’s presentation:
|
Unaudited
Condensed Consolidated Balance Sheet as of September 30, 2026 |
|
Axalta
Group Financial Statement Line |
Axalta
Group Historical Amount |
Axalta
Group Historical Amount |
Reclassification |
|
IFRS
Conversion |
|
Axalta
Group Historical Reclassified Amount |
AkzoNobel
Group Financial Statement Line |
| (€ millions, unless otherwise stated) |
($) |
(i) |
(ii) |
|
(iii) |
|
|
|
| Assets |
|
|
|
|
|
|
|
|
| Current assets: |
|
|
|
|
|
|
|
|
| Cash and cash equivalents |
650 |
572 |
5 |
(a) |
|
|
577 |
Cash and cash equivalents |
| Restricted cash |
6 |
5 |
(5) |
(a) |
|
|
— |
|
| |
— |
— |
84 |
(b) |
(39) |
(b) |
45 |
Current tax assets |
|
Accounts and notes receivable,
net |
1,366 |
1,203 |
85 |
(b) |
|
|
1,288 |
Trade and other receivables |
| Inventories |
849 |
748 |
|
|
|
|
748 |
Inventories |
| Prepaid expenses and other current assets |
192 |
169 |
(169) |
(b) |
|
|
— |
|
| Total current assets |
3,063 |
2,697 |
— |
|
(39) |
|
2,658 |
Total current assets |
| |
— |
— |
36 |
(h) |
103 |
(a) |
139 |
Right-of-use assets |
|
Property, plant and equipment,
net |
1,319 |
1,162 |
(109) |
(c) |
|
|
1,017 |
Property, plant and equipment |
| |
|
|
(36) |
(h) |
|
|
|
|
| Goodwill |
1,762 |
1,552 |
(1,552) |
(d) |
|
|
— |
|
| Identifiable intangibles, net |
1,056 |
930 |
122 |
(c) |
|
|
2,604 |
Intangible assets |
| |
|
|
1,552 |
(d) |
|
|
|
|
| Other assets |
547 |
482 |
(13) |
(c) |
(97) |
(a) |
394 |
Other non-current assets |
| |
|
|
|
|
22 |
(b) |
|
|
| Total assets |
7,747 |
6,823 |
— |
|
(11) |
|
6,812 |
Total assets |
| Liabilities, Shareholders’ Equity |
|
|
|
|
|
|
|
|
| Current liabilities: |
|
|
|
|
|
|
|
|
| Accounts payable |
780 |
687 |
510 |
(e) |
|
|
1,197 |
Trade and other payables |
| |
— |
— |
53 |
(e) |
|
|
53 |
Current tax liabilities |
| |
— |
— |
29 |
(e) |
|
|
29 |
Current portion of provisions |
| Current portion of borrowings |
519 |
457 |
|
|
26 |
(a) |
483 |
Short-term borrowings |
| Other accrued liabilities |
701 |
618 |
(592) |
(e) |
(26) |
(a) |
— |
|
| Total current liabilities |
2,000 |
1,762 |
— |
|
— |
|
1,762 |
Total current liabilities |
| Long-term borrowings |
2,476 |
2,181 |
|
|
70 |
(a) |
2,251 |
Long-term borrowings |
| Accrued pensions |
225 |
198 |
(198) |
(g) |
|
|
— |
|
| Deferred income taxes |
182 |
160 |
(160) |
(g) |
|
|
— |
|
| Other liabilities |
198 |
174 |
358 |
(g) |
(70) |
(a) |
450 |
Provisions and deferred tax liabilities |
| |
|
|
|
|
(12) |
(b) |
|
|
| Total liabilities |
5,081 |
4,475 |
— |
|
(12) |
|
4,463 |
|
| Commitments and contingent liabilities |
|
|
|
|
|
|
|
|
| Shareholders’ equity: |
|
|
|
|
|
|
|
|
| |
— |
— |
2,308 |
(f) |
6 |
(a) |
2,309 |
Shareholders’ equity |
| |
|
|
|
|
(5) |
(b) |
|
|
| Common shares |
256 |
225 |
(225) |
(f) |
|
|
— |
|
| Capital in excess of par |
1,637 |
1,442 |
(1,442) |
(f) |
|
|
— |
|
| Retained earnings |
2,329 |
2,051 |
(2,051) |
(f) |
|
|
— |
|
| Treasury shares, at cost |
(1,202) |
(1,058) |
1,058 |
(f) |
|
|
— |
|
| Accumulated other comprehensive loss |
(400) |
(352) |
352 |
(f) |
|
|
— |
|
|
Total Axalta shareholders’
equity |
2,620 |
2,308 |
— |
|
1 |
|
2,309 |
|
| Noncontrolling interests |
46 |
40 |
|
|
|
|
40 |
Non-controlling interests |
| Total shareholders’ equity |
2,666 |
2,348 |
— |
|
1 |
|
2,349 |
|
| Total liabilities and shareholders’ equity |
7,747 |
6,823 |
— |
|
(11) |
|
6,812 |
Total equity and liabilities |
Unaudited Condensed Consolidated Statement
of Income for the Nine Months Ended September 30, 2026
|
|
Axalta
Group Financial Statement Line |
Axalta
Group Historical Amount |
Axalta
Group Historical Amount |
Reclassification |
|
IFRS
Conversion |
|
Axalta
Group Historical Reclassified Amount |
AkzoNobel
Group Financial Statement Line |
| (€ millions, unless otherwise stated) |
($) |
(i) |
(ii) |
|
(iii) |
|
|
|
| Net sales |
3,911 |
3,369 |
|
|
|
|
3,369 |
Revenue |
| Cost of goods sold |
2,596 |
2,236 |
(420) |
(a) |
18 |
(a) |
1,798 |
Cost of sales |
| |
|
|
|
|
(22) |
(a) |
|
|
| |
|
|
|
|
(14) |
(c) |
|
|
| Selling, general and administrative expenses |
614 |
529 |
420 |
(a) |
14 |
(c) |
1,076 |
Selling, general and administrative (SG&A) costs |
| |
|
|
113 |
(b) |
|
|
|
|
| Other operating charges |
92 |
79 |
|
|
|
|
79 |
Others results |
| Research and development expenses |
54 |
47 |
(47) |
(b) |
|
|
– |
|
| Amortization of acquired intangibles |
77
|
66
|
(66)
|
(b) |
|
|
–
|
|
| Income from operations |
478
|
412
|
–
|
|
4
|
|
416
|
Operating income |
| |
– |
– |
97 |
(c) |
4 |
(a) |
101 |
Finance income and expenses |
| Interest expense, net |
112 |
97 |
(97) |
(c) |
|
|
– |
|
| Other expense (income), net |
(1) |
(1) |
1 |
(c) |
|
|
– |
|
| |
–
|
–
|
(1) |
(c) |
|
|
(1)
|
Results from associates |
| Income before income taxes |
367 |
316 |
– |
|
– |
|
316 |
Profit before tax |
| Provision for income taxes |
92
|
79
|
|
|
|
|
79
|
Income tax |
| Net income |
275 |
237 |
– |
|
– |
|
237 |
Profit for the period |
| Less: Net income attributable to noncontrolling interests |
1
|
1
|
|
|
|
|
1
|
Non-controlling interests |
| Net income attributable to common shareholders |
274
|
236
|
–
|
|
–
|
|
236
|
Shareholders of the company |
| Weighted average number of common shares |
|
|
|
|
|
|
|
|
| Basic |
213.9 |
|
|
|
|
|
213.9 |
|
| Diluted |
214.8 |
|
|
|
|
|
214.8 |
|
| Earnings per share |
|
|
|
|
|
|
|
|
| Basic |
1.28 |
|
|
|
|
|
1.10 |
|
| Diluted |
1.28 |
|
|
|
|
|
1.10 |
|
| (i) | The financial statements of Axalta Group have been translated into EUR for the purposes of presentation
in the Pro Forma Financial Information using the following exchange rates: |
| a) | The spot rate as of September 30, 2026 of $1.00 to €0.88 for the unaudited pro forma condensed combined
balance sheet as of September 30, 2026. |
| b) | The average exchange rate for the period January 1, 2026 through September 30, 2026 of $1.00 to €0.86
for the unaudited pro forma condensed combined statement of income for the nine months ended September 30, 2026. |
| (ii) | Reflects reclassification adjustments to conform Axalta Group’s historical balances to the financial
statement presentation of AkzoNobel Group. |
| · | Unaudited Condensed Consolidated Balance Sheet Impact: |
| (a) | Represents the reclassification of historical Axalta Group’s restricted cash to cash and cash equivalents. |
| (b) | Represents the reclassification of historical Axalta Group’s accounts and notes receivable, prepaid
expenses and other current assets to trade and other receivables and current tax assets. |
| (c) | Represents the reclassification of historical Axalta Group’s capitalized software and cloud computing
arrangements within property, plant and equipment and other assets to intangible assets. |
| (d) | Represents the reclassification of historical Axalta Group’s goodwill to intangible assets. |
| (e) | Represents the reclassification of historical Axalta Group’s other accrued liabilities to trade
and other payables, current tax liabilities and current portion of provisions. |
| (f) | Represents the aggregation of historical Axalta Group’s common shares, capital in excess of par,
retained earnings, treasury shares and accumulated other comprehensive loss to shareholders’ equity. |
| (g) | Represents the reclassification of historical Axalta Group’s accrued pensions and deferred income
taxes and other current liabilities to provisions and deferred tax liabilities. |
| (h) | Represents the reclassification of historical Axalta Group’s finance leases within property, plant
and equipment to right-of-use assets. |
| · | Unaudited Condensed Consolidated Statement of Income Impact: |
| (a) | Represents the reclassification of certain amounts of historical Axalta Group’s cost of sales to
selling, general and administrative costs, primarily related to the costs of outbound logistical services as well as costs related to
other functional costs supporting manufacturing. |
| (b) | Represents the reclassification of historical Axalta Group’s research and development expenses and
amortization of acquired intangibles to selling, general and administrative costs. |
| (c) | Represents the reclassification of historical Axalta Group’s interest expense, net, and other expense
(income), net to finance income and expenses and, where applicable, results from associates. |
| (iii) | The historical consolidated financial statements of Axalta Group have been converted from U.S. GAAP to
IFRS, applying AkzoNobel Group’s IFRS accounting policies. |
Based on a preliminary review performed
by AkzoNobel Group of Axalta Group’s historical consolidated financial statements, the following adjustments have been made to reflect
Axalta Group’s historical consolidated balance sheet and consolidated statement of income on an IFRS basis for the purposes of the
Pro Forma Financial Information.
| a) | Leases: Under U.S. GAAP, lessees are required to classify their leases as either finance leases
or operating leases. Under IFRS, however, lessees apply a single lease accounting model that is broadly similar to the finance lease model
under U.S. GAAP. As a result, the following adjustments have been made for the Axalta Group’s operating lease under IFRS. |
| · | Unaudited Condensed Consolidated Balance Sheet Impact: Reflects the reclassification of operating
lease right-of use-assets presented within Other assets to Right-of-use assets. Further, reflects the reclassification of operating lease
liabilities presented within Other accrued liabilities and within Other liabilities to Short-term borrowings and Long-term borrowings,
respectively. |
| |
As of September 30, 2026 |
| |
(€ millions) |
| Decrease in Other assets |
97 |
| Increase in Shareholders’ equity |
6 |
| Increase in Right-of-use assets |
103 |
| Decrease in Other accrued liabilities |
26 |
| Increase in Short-term borrowings |
26 |
| Decrease in Other liabilities |
70 |
| Increase in Long-term borrowings |
70 |
| § | Unaudited Condensed Consolidated Statement of Income Impact: Reflects the recognition of depreciation
on right-of-use assets within Cost of sales related to operating leases which have been reclassified to financing leases with IFRS. Further,
reflects the derecognition of operating lease cost within Cost of sales related to leases which have been reclassified to Right-of-use
assets and recognition of incremental Finance expense on lease liabilities. |
| |
For the Nine Months Ended September 30, 2026 |
| |
(€ millions) |
| Increase in Cost of sales |
18 |
| Decrease in Cost of sales |
22 |
| Increase in Finance expenses |
4 |
| b) | Taxes on Intra-Entity Transfers of Inventories: Under U.S. GAAP, the tax effect of intra-entity
transfers of inventories are deferred until the related inventories are sold or disposed of, and no deferred taxes are recognized for
the difference between the carrying value of the inventories in the consolidated financial statements and the tax basis of the inventories
in the buyer’s tax jurisdiction. In addition, the tax paid or payable from the intra-entity transfer is deferred upon consolidation
and is not included in tax expense until the inventories are sold to an unrelated third party. Under IFRS, there is no exception for recognizing
such tax consequences of intra-entity transfers of inventory. The following adjustments have been made to Axalta Group’s tax balances
under IFRS: |
| |
As of September 30, 2026 |
| |
(€ millions) |
| Decrease in Current tax assets |
39 |
| Increase in Other non-current assets |
22 |
| Decrease in Provisions and deferred tax liabilities |
12 |
| Decrease in Shareholders’ equity |
5 |
| c) | Inventory: Under U.S. GAAP, inventory write-offs of finished goods are reflected within Cost of
sales; however, AkzoNobel Group reflects these charges within Selling, general and administrative costs, which is allowable under IFRS.
As a result, the following adjustments have been made for the Axalta Group’s inventory write-offs under IFRS. |
| |
For the Nine Months Ended September 30, 2026 |
| |
(€ millions) |
| Decrease in Cost of sales |
14 |
| Increase in Selling, general and administrative costs |
14 |
3. Adjustments to the Unaudited Pro Forma
Condensed Combined Balance Sheet as of September 30, 2026
| (A) | Reflects purchase price consideration as well as the purchase price allocation adjustments to record Axalta
Group’s assets and liabilities at estimated fair value based on the consideration conveyed. |
The preliminary purchase price was allocated
among the identified assets to be acquired, based on a preliminary analysis. Goodwill is expected to be recognized as a result of the
transaction, which represents the excess of the fair value of consideration over the fair value of the underlying net assets of Axalta
Group. This was considered appropriate based on the determination that the transaction would be accounted for under the acquisition method
under IFRS 3. The deferred income taxes represent the deferred tax impact associated with the incremental differences in book and tax
basis created from the preliminary purchase price allocation. Deferred taxes associated with estimated fair value adjustments were calculated
using the weighted average statutory income tax rate of 25.2%. The estimates of fair value are based upon preliminary valuation assumptions,
and are believed to be reasonable, but are inherently uncertain and unpredictable. As a result, actual results may differ from estimates,
and the difference may be material.
The following is a preliminary estimate
of the assets acquired and the liabilities assumed by AkzoNobel Group in the transaction, reconciled to the estimated purchase consideration:
| Net Assets Identified |
Preliminary Estimate of Fair Value |
| |
| (€ millions) | |
| Intangible assets(1) |
| 6,748 | |
| Property, plant and equipment(2) |
| 1,601 | |
| Right-of-use assets |
| 139 | |
| Other non-current assets |
| 394 | |
| Inventories(3) |
| 910 | |
| Trade and other receivables |
| 1,288 | |
| Current tax assets |
| 45 | |
| Cash and cash equivalents |
| 577 | |
| Non-controlling interests |
| (35 | ) |
| Provisions and deferred tax liabilities |
| (1,240 | ) |
| Short-term borrowings |
| (483 | ) |
| Long-term borrowings |
| (2,251 | ) |
| Trade and other payables |
| (1,197 | ) |
| Current tax liabilities |
| (53 | ) |
| Current portion of provisions |
| (29 | ) |
| Total Net Assets Identified |
| 6,414 | |
| Value Conveyed |
| | |
| Equity Consideration(4) |
| 6,378 | |
| Stock-based Compensation(5) |
| 36 | |
| Total Preliminary Purchase Consideration |
| 6,414 | |
| (1) | Intangible assets were comprised of the following: |
| Asset type | |
Fair value | |
Weighted Average Remaining Useful Life | |
Valuation methodology |
| | |
| (€ millions) | | |
| |
|
| Customer relationships | |
| 2,133 | | |
17.2 years | |
Multi-period excess earnings |
| Technology | |
| 617 | | |
10.0 years | |
Relief-from-royalty |
| Brand names | |
| 558 | | |
21.2 years | |
Relief-from-royalty |
| Software | |
| 125 | | |
10.0 years | |
Cost approach |
| Goodwill | |
| 3,315 | | |
N/A | |
IFRS 3 |
| Total intangible assets | |
| 6,748 | | |
| |
|
| (2) | The property, plant and equipment fair value was primarily related to building and improvements, which
accounted for 28% of the balance, and machinery and equipment, which accounted for 48% of the balance. These asset groups in AkzoNobel
Group’s property, plant and equipment are included within the subcategory of land and buildings and plant equipment and machinery,
respectively. The estimated weighted average remaining useful life of building and improvements and machinery and equipment was 17 years
and 4.7 years, respectively. |
| (3) | Reflects the fair value of inventories as a result of the transaction. Raw materials inventory is assumed
to be at market value, and the adjustment is related to finished products and semi-finished products. The fair value of finished products
and semi-finished products to be acquired in the transaction is determined based on an analysis of estimated future selling prices, costs
of disposal, holding costs and estimated profit allowance for the selling effort of the acquiring entity based on profit for similar products. |
| (4) | Equity consideration was calculated as 140 million shares of AkzoNobel Group ordinary shares to be issued
to existing Axalta Group shareholders (i.e., Axalta Group’s outstanding common shares equal to 214 million as of September 30, 2026,
multiplied by the exchange ratio of 0.6539), multiplied by €45.58, the adjusted per share value of AkzoNobel Group (i.e., calculated
as the closing share price of AkzoNobel Group ordinary shares on October 23, 2026 equal to €58.62, multiplied by the AkzoNobel Group
ordinary shares outstanding equal to 171 million (approximately) as of October 23, 2026, less the special dividend of €2,500 million
net of paid dividends of €264 million, divided by AkzoNobel Group ordinary shares outstanding). |
A 10% fluctuation in the share price of
AkzoNobel ordinary shares would change the value of the preliminary purchase consideration reflected in the Pro Forma Financial Information
by €639 million with a corresponding change to goodwill related to the transaction. The average opening and closing price for the
pro forma period of January 1, 2025 through September 30, 2026 each varied from the share price used in calculating consideration by approximately
2%,. The maximum share price during this period varied by 15%, and the minimum share price during this period varied by 21%.
| (5) | Determination of consideration related to stock-based compensation required an allocation of the market-based
measure under IFRS 3 between pre-combination compensation expense (i.e. purchase consideration) and post-combination compensation expense,
which was determined using the adjusted per share value of AkzoNobel ordinary shares of €45.58 (as described in footnote 4 above)
and the closing share price of Axalta common shares on October 23, 2026 of $34.14, or €30.50. |
| (B) | Reflects €159 million of nonrecurring expenses related to estimated transaction costs. Of this amount,
€88 million related to investment banking fees expected to be incurred by Axalta Group; this amount was not reflected as an income
statement adjustment as it is not an expense of the accounting acquirer or of MergeCo. The remaining €71 million related to AkzoNobel
Group’s estimated transaction costs, which are primarily comprised of investment banking fees, legal fees, accounting and audit
fees, and other related advisory costs. The related income statement adjustment associated with AkzoNobel Group’s nonrecurring transaction
costs is not reflected in the unaudited pro forma condensed combined statement of income for the nine months ended September 30, 2026. |
| (C) | Reflects recognition of pre-completion distribution to be paid by AkzoNobel prior to the effective time
(as defined below) of the transaction in an aggregate amount of €2.2 billion. |
| (D) | Reflects the payment at completion of €33 million in cash retention bonuses to individuals at both
AkzoNobel Group and Axalta Group. An additional €38 million will be payable six months after completion. AkzoNobel Group had accrued
€20 million in respect of these retention bonuses on its balance sheet as of September 30, 2026. The related income statement adjustment
is not reflected in the unaudited pro forma condensed combined statement of income for the nine months ended September 30, 2026. |
| (E) | Reflects the issuance of additional debt in an aggregate principal amount of €1.1 billion, as described
in the section entitled “The Financing Transactions.” The related income statement adjustment is reflected at adjustment (CC). |
| (F) | Reflects the repayment of the Axalta 2029 Dollar Term Loans in an aggregate principal amount of €1.1
billion. The related income statement adjustment is reflected at adjustment (DD). |
3. Adjustments to the Unaudited Pro Forma Condensed
Combined Statement of Income for the Nine Months Ended September 30, 2026
| (AA) | Reflects the pro forma impacts related to the purchase price allocation discussed at adjustment (A). This
includes the following impacts: |
| · | Depreciation expense on Property, plant and equipment: Reflects an increase in depreciation expense
recorded in Cost of sales in the amount of €43 million for the nine months ended September 30, 2026. This increase is primarily related
to Buildings and improvements and Machinery and equipment and was calculated using the estimated weighted
average remaining useful life of 17 years and 4.7 years, respectively. |
| · | Amortization expense on Intangible assets: Reflects an increase in amortization expense recorded
in selling, general and administrative costs of €92 million for the nine months ended September 30, 2026. This change is related
to Customer relationships, Software, Technology and Brand names and was calculated using the estimated weighted average remaining useful
lives of 17.2 years, 10.0 years, 10.0 years and 21.2 years, respectively. |
| (BB) | Reflects the tax impact of all pro forma adjustments for the nine months ended September 30, 2026, calculated
using the weighted average statutory income tax rate of 25.2%. |
| (CC) | Reflects estimated interest expense related to (i) the issuance of additional debt, as presented at adjustment
(E), calculated using an estimated interest rate of 6.3%; and (ii) the March and June senior notes, using fixed coupons of 4.0% and 3.6%,
respectively, after deducting modeled interest already recorded on those notes. The June-note deduction assumes issuance on June 1, 2026.
An increase or decrease of one-eighth of a percent in the interest rate related to the issuance of additional debt would not result in
a significant change in interest expense for the nine months ended September 30, 2026. |
| (DD) | Reflects the elimination of interest expense related to the Axalta 2029 Dollar Term Loans. |
4. Unaudited Pro Forma Earnings per Share
Unaudited pro forma earnings
per share calculations are based on the consolidated pro forma weighted average shares outstanding of AkzoNobel Group. The pro forma net
income per share calculations have been performed for the nine months ended September 30, 2026, assuming the transaction occurred on January
1, 2025.
| (in € millions except per share amounts) |
|
For the Nine Months Ended September 30, 2026 |
| Pro forma profit for the period |
|
|
| Weighted average number of common shares |
|
179 |
| Number of shares: |
|
|
| AkzoNobel Group |
|
171 |
| Axalta Group legacy shareholders. |
|
140 |
| Shares for basic earnings per share for the year |
|
311 |
| Effect of dilutive shares: |
|
|
| AkzoNobel Group |
|
– |
| Axalta Group legacy shareholders |
|
1 |
| Shares for diluted earnings per share |
|
312 |
| |
|
|
| Pro forma earnings per share |
|
|
| Basic |
|
0.58 |
| Diluted |
|
0.57 |
definitions
As used herein, except where
noted or the context otherwise requires:
| · | “AkzoNobel ordinary shares” refers to the common shares, par value €0.50 per share, of
AkzoNobel. |
| · | “Axalta common shares” refers to the common shares, par value of $1.00 per share, of Axalta. |
| · | “Axalta credit agreement” refers to the credit agreement, dated February 1, 2013, by and among
Axalta Coating Systems Dutch Holding B B.V., a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid)
organized and established under the laws of the Netherlands, having its corporate seat in Amsterdam, the Netherlands, registered with
the Trade Register of the Netherlands under number 55948308, Axalta Coating Systems U.S. Holdings, Inc., a corporation organized under
the laws of Delaware, Axalta Coating Systems U.S., Inc. a Delaware corporation, Axalta, the lenders from time to time party thereto and
Barclays Bank PLC as administrative agent and collateral agent, as amended, restated, amended and restated, supplemented or otherwise
modified from time to time. |
| · | “Axalta shareholder” refers to a holder of Axalta common shares. |
| · | “completion date” refers to the date of completion. AkzoNobel and Axalta expect to complete
the transaction in early 2027, assuming the conditions to completion (described under the section of the Form F-4 in the section entitled
“The Merger Agreement—Conditions to the Merger”) are satisfied. |
| · | “effective time” refers to the time that the certificate of merger is issued by the Bermuda
Registrar of Companies, or such other time and date as shall be set forth in the certificate of merger, in each case, with respect to
the transaction. |
| · | “MergeCo” refers to the successor by name change to AkzoNobel upon completion, which legal
entity will be the parent entity of the combined group consisting of AkzoNobel Group and Axalta Group following completion of the transaction. |
| · | “pre-completion distribution” refers to the special cash dividend, which AkzoNobel will declare
and pay prior to the effective time (subject to applicable law and any applicable withholding tax), for an aggregate amount of €2.5
billion minus the aggregate amount of any regular annual and interim dividends declared by AkzoNobel with record dates in 2026
prior to the record date of the pre-completion distribution.
|